Dr. Boughey on Reducing False Negatives in SLN Surgery

Judy C. Boughey, MD
Published: Wednesday, Dec 05, 2012

Judy C. Boughey, MD, associate professor of surgery at the Mayo Clinic in Rochester, Minnesota, discusses surgical techniques examined in the American College of Surgeons Oncology Group (ACOSOG) Z1071 study that could help minimize the false negative rates experienced with sentinel lymph node (SLN) surgery.

The Z1071 trial found that SLN surgery was able to detect residual nodal disease in approximately 91.2% of women with early-stage breast cancer, following neoadjuvant chemotherapy. However, the false negative rate for those receiving SLN surgery was 12.6%. Boughey notes that a clinically acceptable false negative rate is generally considered to be 8-10%, warranting further investigation into approaches that reduce this rate.

In general, the Z1071 trial found that using both a blue dye and radiolabeled colloid mapping agent decreased the false negative rate to 10.8% and when more than 3 SLN were examined the rate decreased to 9.1%. Combining these approaches could further reduce the false negative rate into a clinically acceptable level, Boughey believes.

<<< View coverage from the 2012 SABCS

Judy C. Boughey, MD, associate professor of surgery at the Mayo Clinic in Rochester, Minnesota, discusses surgical techniques examined in the American College of Surgeons Oncology Group (ACOSOG) Z1071 study that could help minimize the false negative rates experienced with sentinel lymph node (SLN) surgery.

The Z1071 trial found that SLN surgery was able to detect residual nodal disease in approximately 91.2% of women with early-stage breast cancer, following neoadjuvant chemotherapy. However, the false negative rate for those receiving SLN surgery was 12.6%. Boughey notes that a clinically acceptable false negative rate is generally considered to be 8-10%, warranting further investigation into approaches that reduce this rate.

In general, the Z1071 trial found that using both a blue dye and radiolabeled colloid mapping agent decreased the false negative rate to 10.8% and when more than 3 SLN were examined the rate decreased to 9.1%. Combining these approaches could further reduce the false negative rate into a clinically acceptable level, Boughey believes.

<<< View coverage from the 2012 SABCS


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x